MSB Docs celebrated eight pharma industry customer wins yesterday, according to a press release.
MSB Docs and Contract Research and Development Organization (CRDO) in Ithaca, New York, collaborated on using solutions for 21 CFR Part 11 contracts between CROs and pharmaceutical corporations. Medical device, pharmaceutical, and consumer product companies can use the company’s development and testing services. Biocompatibility, innovative coating, antibacterial, peptide, innovative coating, and protein applications are among its areas of competence, according to the release.
It further said that MSB Docs solutions are used for 21 CFR Part 11 contracts between CRO and pharma firms by Irvine, California-based life sciences platform enabling next-generation trials to create safe and effective therapies. With its big data platform, the firm accelerates the adoption of digital health in research by delivering low-barrier-to-entry analytics as a service.
With the integration of e-signature and digital smart document technologies, Murray, a US-based CRO, has taken use of MSB Docs’ exceptional domain experience for the pharma business.
According to the announcement, MSB Docs solutions are being used by a clinical research leader in Toronto, Canada, for 21 CFR Part 11 contracts between CROs and pharmaceutical firms. To progress, the organization collaborates with industry and the healthcare community.
The group collaborates with the pharmaceutical industry and the healthcare community to improve therapeutic treatment alternatives. Since its founding, it has performed over 200 phase II, III, and IV research studies with over 700 physicians treating over three million individuals.
MSB Docs is being integrated with their software for e-signing by New York-based pharmacovigilance, e-clinical, and commercialization solutions. Every year, the firm completes around 400,000 tasks. It employs over 6,000 full-time employees, has a network of over 10,000 certified linguists and subject-area specialists, and has offices in over 100 locations worldwide.
MSB Docs has been incorporated into the process of developing and commercializing novel treatments for cancer and rare disorders by a London-based biopharmaceutical company. According to the statement, its clinical research colleagues now spend more time on their trials and less time chasing paper.
With MSB Docs integration, a pharma company situated in Osaka, Japan, is enhancing the efficiency and turnaround time of the product development lifecycle. It stated it had altered its handling of sensitive and private documents across the whole process, from R&D through clinical testing to the introduction of a new medicine and storage for regulatory compliances.
In all elements of clinical trials, a scientific and site management organization for paediatric infectious diseases and immunology situated in Buenos Aires, Argentina is boosting quality, growth, efficiency, and client experience across sponsors, CROs, and investigators. The statement stated that the large number of daily contracts and agreements have eliminated the paper-intensive work, resulting in considerable improvements in contract preparation and completion rates, approval process, and forecasting and execution capabilities.